PIONEER
What it found
No result yet.
What was tested
Treatment tested
- Ponesimod
Sphingosine 1-phosphate receptor Edg-1 agonist
Compared with
What it measured
Main measures
Time from randomization to first confirmed relapse
Relapses
Other measures (1)
a. ARR, defined as the number of confirmed relapses per participant year
Relapses
Who could take part
Relapsing MS
Inclusion: - A diagnosis of relapsing-remitting multiple sclerosis (RRMS) as defined by the 2017 revisions of the McDonald criteria. Central review of the diagnosis of pediatric multiple sclerosis (MS) will be required for all participants prior to Visit 3 (Day 1, randomization). Exclusion: - Presenting with a diagnosis of MS with progressive course from onset (that is, primary progressive MS or progressive relapsing MS).
As registered. Criteria can change, so ask the trial team or your neurologist.
About this trial
In the sponsor's words
The primary objective is to demonstrate that ponesimod is not less effective than fingolimod in reducing relapses in pediatric participants with relapsing remitting multiple sclerosis (RRMS) if treatment is taken as directed through Week 108
Papers
Loading reviews and guidelines…
Related trials
- VOYAGE
Phase 3 · Not yet recruiting
Still running
- TG1101-RMS-PED304
Phase 2 / Phase 3 · Recruiting
Still running
- IM047-050
Phase 3 · Recruiting
Still running
- COAST
Phase 4 · Recruiting
Still running
- Assessing the Cognitive Benefits of Ozanimod and Their Br…
Phase 4 · Withdrawn
Stopped early
- A Study to Assess the Effectiveness and Safety of Ozanimo…
Phase 4 · Running, not recruiting
Still running
History
Started
Aug 2022
Assembled by software from public sources and not checked by people. Each record links to its source. Report an error